GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cryomass Technologies Inc (OTCPK:CRYM) » Definitions » Altman Z-Score

Cryomass Technologies (Cryomass Technologies) Altman Z-Score : N/A (As of May. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cryomass Technologies Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Cryomass Technologies has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Cryomass Technologies's Altman Z-Score or its related term are showing as below:

During the past 12 years, Cryomass Technologies's highest Altman Z-Score was 335.90. The lowest was -2.20. And the median was 7.96.


Cryomass Technologies Altman Z-Score Historical Data

The historical data trend for Cryomass Technologies's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryomass Technologies Altman Z-Score Chart

Cryomass Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.01 15.21 -2.20 - -

Cryomass Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cryomass Technologies's Altman Z-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Cryomass Technologies's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryomass Technologies's Altman Z-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cryomass Technologies's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Cryomass Technologies's Altman Z-Score falls into.



Cryomass Technologies Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Cryomass Technologies's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-1.6399+1.4*-45.1735+3.3*-13.7556+0.6*2.3437+1.0*0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2023:
Total Assets was $1.07 Mil.
Total Current Assets was $0.22 Mil.
Total Current Liabilities was $1.98 Mil.
Retained Earnings was $-48.43 Mil.
Pre-Tax Income was -1.454 + -6.362 + -1.599 + -5.633 = $-15.05 Mil.
Interest Expense was -0.109 + -0.083 + -0.054 + -0.056 = $-0.30 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $10.52 Mil.
Total Liabilities was $4.49 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.222 - 1.98)/1.072
=-1.6399

X2=Retained Earnings/Total Assets
=-48.426/1.072
=-45.1735

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-15.048 - -0.302)/1.072
=-13.7556

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=10.523/4.49
=2.3437

X5=Revenue/Total Assets
=0/1.072
=0

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Cryomass Technologies has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Cryomass Technologies  (OTCPK:CRYM) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Cryomass Technologies Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Cryomass Technologies's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryomass Technologies (Cryomass Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1001 Bannock Street, Suite 612, Denver, CO, USA, 80204
Cryomass Technologies Inc designs, manufactures, and licenses field-mobile equipment for the handling of harvested cannabis, hemp, and other high-value plant material. The company owns patented technology that utilizes liquid nitrogen to fully separate, collect and protect the high-value compounds from the harvested plant. The company's offerings include refinement systems and monitoring and control systems.
Executives
Philip Blair Mullin officer: Chief Financial Officer 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Christian Noel director, officer: Chief Executive Officer 3531 SOUTH LOGAN ST. SUITE D-357, ENGLEWOOD CO 80113
Patricia Izabel Kovacevic officer: GC, Corp Secy, and Head of EA 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Delon Hannes Human director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Mark Radke director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Mario Gobbo director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113